Trial · NCT05244057
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
NCT05244057, Phase 2, Completed, Shanghai HEP Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients. Trials, record NCT05244057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05244057
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
- NCT number
- NCT05244057
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Conditions
- Chronic Hepatitis B
- Interventions
- Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets, Pegylated Interferon alfa 2a
- First posted
- 2022-02-17
- Last updated
- 2024-07-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects with negative conversion of HBsAg | 56 Weeks | Proportion of subjects with negative conversion of HBsAg treatment at 8 weeks off treatment |
| Secondary | Number of subjects with virological relapse(VR) at 8 weeks off treatment | 56 Weeks | VR: reappearance of HBV DNA \> 2000 IU/ml from undetectable status |
| Secondary | Number of subjects with clinical relapse(CR) at 8 weeks off treatment | 56 Weeks | CR: the presence of VR with the elevation of alanine transaminase (ALT) more than two times upper limit of normal (ULN) |
| Secondary | HBsAg is down from baseline at 8 weeks off treatment | 56 Weeks | HBsAg is down from baseline log10 |
| Secondary | Number of subjects with Serological conversion of HBsAg | 56 Weeks | Number of subjects with Serological conversion of HBsAg at 8 weeks off treatment |
| Secondary | Change in liver stiffness at 8 weeks off treatment | 56 Weeks | The findings of Liver stiffness measurement(LSM) of Fibroscan/FibroTouch at week 8 off treatment compared to baseline |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05244057
GET https://conductscience.org/api/trials/v1/NCT05244057/registered